- Peptide Substrates
- Binding Proteins
- Secondary Antibodies
- Regulatory proteins
- 脂类激酶
- 双加氧酶与蛋白质
- 脂质底物
- E2
- Assay Buffer and Co-factors
- Methyltransferases
- Acetyltransferases
- Transcription Proteins
- COVID-19 ELISA Kits
- Tau Proteins
- Microtubule & Actin Associated Proteins
- Carbohydrate Substrates
- COVID-19 Proteins
- Chemokines
- 标记抗体
- 授予称号
- E3
Overview:
RET/PTC3 is fused of RET and the activating NCOA4 gene by intrachromosomal paracentric inversions in chromo-some 10 (1). Likes RET/PTC1, it is the most frequent RET rearrangements in papillary thyroid carcinoma (PTC) (2), especially in radiation-induced tumours. The RET/PTC3 rearrangements may be typical for radiation-induced childhood PTC with a short latency period (3). The RET/PTC rearrangements also have been shown in benign thyroid lesions, including Hashimoto"s thyroiditis (HT).
Gene Aliases:
NCOA4:ELE1, RFG, ARA70, PTC3, DKFZp762E1112RET:CDHF12, RET51, PTC, RET-ELE1; RET/PTC3
Genbank Number:
BC001562NM_020630
References:
1. Santoro M, et al: Molecular characterization of RET/PTC3; a novel rearranged version of the RET proto-oncogene in a human thyroid papillary carcinoma. Oncogene 1994, 9:509-516.2. Nikiforov YE: RET/PTC rearrangement in thyroid tumors. Endocr Pathol 2002, 13:3-16.3. Smida J. et al: Distinct frequency of ret rearrangements in papillary thyroid carcinomas of children and adults from Belarus. Int J Cancer 1999, 80:32-38.
